Evicenter
P&T meetings

Imlifidase

Kidney transplantation in highly sensitized patients

Manufacturer
Hansa Biopharma
Regulatory submission
BLA submitted December 2025
Last updated
85 sources

Product information and disease descriptionProduct descriptionProduct information

Special populations

1 evidence topic · 1 source

Hepatic impairment and pediatric populations
PopulationQuoted safety and efficacy information
Moderate or severe hepatic impairment“have not been established. No data are available.”
Children and adolescents younger than 18 years“No data are available.”